{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:44:41Z","timestamp":1791229481477,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,8,1]],"date-time":"2000-08-01T00:00:00Z","timestamp":965088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2000,8]]},"DOI":"10.1067\/mjd.2000.104001","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T00:20:13Z","timestamp":1027556413000},"page":"403-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"special_numbering":"P2","title":["Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg)"],"prefix":"10.1067","volume":"43","author":[{"given":"Robert K.","family":"Lister","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Jolles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Whittaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Forgacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cramp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm H.A.","family":"Rustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mjd.2000.104001_bib1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0190-9622(95)90007-1","article-title":"Scleromyxoedema","volume":"33","author":"Dinneen","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib2","first-page":"107","article-title":"Scleromyxoedema (lichen myxoedematosus) associated with a paraprotein,IgG of type kappa","volume":"88","author":"Lai","year":"1973","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib3","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/archderm.1975.01630220089007","article-title":"Lichen myxedematosus: a dermal infiltrative disorder responsive to cyclophosphamide therapy","volume":"111","author":"Hoursden","year":"1975","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0190-9622(93)70021-K","article-title":"The association of potentially lethal neurologic syndromes with scleromyxoedema (papular mucinosis)","volume":"28","author":"Webster","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1093\/ajcp\/69.4.446","article-title":"Scleromyxoedema myopathy: histochemical and electromicroscopic observations","volume":"69","author":"Verity","year":"1978","journal-title":"Am J Clin Pathol"},{"key":"10.1067\/mjd.2000.104001_bib6","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/art.1780290716","article-title":"Scleromyxoedema with systemic involvement mimics rheumatic diseases","volume":"29","author":"Fudman","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1067\/mjd.2000.104001_bib7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-4362.1989.tb02436.x","article-title":"Scleromyxoedema and severe myositis","volume":"28","author":"Rothe","year":"1989","journal-title":"Int J Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-4362.1989.tb02437.x","article-title":"Scleromyxoedema","volume":"28","author":"Harris","year":"1989","journal-title":"Int J Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib9","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/art.1780200412","article-title":"Papular mucinosis with myopathy, arthritis and eosinophilia: a histopathologic study","volume":"20","author":"McAdam","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1067\/mjd.2000.104001_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2133.1975.tb06786.x","article-title":"Scleromyxoedema","volume":"93","author":"Kubba","year":"1975","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib11","first-page":"60","article-title":"Scleromyoedema associated with oesophageal aperistalsis and dermal eosinophilia","volume":"28","author":"Alligood","year":"1981","journal-title":"Cutis"},{"key":"10.1067\/mjd.2000.104001_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2133.1984.tb04642.x","article-title":"PUVA treatment of scleromyxoedema","volume":"110","author":"Farr","year":"1984","journal-title":"Br J Derm"},{"key":"10.1067\/mjd.2000.104001_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0190-9622(88)70199-1","article-title":"Scleromyxoedema: therapeutic response to isotretinoin in three patients","volume":"19","author":"Milam","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib14","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2133.1987.tb07499.x","article-title":"Scleromyxoedema successful treatment with plasma exchange and immunosuppression","volume":"117","author":"MacFarlane","year":"1987","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib15","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/S0190-9622(08)80676-7","article-title":"Extracorporeal photochemotherapy: a potentially useful treatment for scleromyxoedema","volume":"25","author":"Berkson","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib16","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2133.1996.d01-1023.x","article-title":"Remission of scleromyxoedema following treatment with extracorporeal photopheresis","volume":"135","author":"Krasagakis","year":"1996","journal-title":"Br J Derm"},{"key":"10.1067\/mjd.2000.104001_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/archderm.1979.04010030003002","article-title":"Treatment of scleromxoedema with melphalan","volume":"115","author":"Harris","year":"1979","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/rheumatology\/31.7.457","article-title":"Reliability of skin involvement measures in scleroderma","volume":"31","author":"Brennan","year":"1992","journal-title":"Br J Rheumatol"},{"key":"10.1067\/mjd.2000.104001_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1001\/archneur.1991.00530140113024","article-title":"Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: clinical and laboratory characteristics associated with improvement","volume":"48","author":"Van Doorn","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1067\/mjd.2000.104001_bib20","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.46.6.1778","article-title":"Fever, convulsions and coma in scleromyxoedema: a \u201cdermato-neuro syndrome.\u201d","volume":"46","author":"River","year":"1996","journal-title":"Neurology"},{"key":"10.1067\/mjd.2000.104001_bib21","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/archderm.1982.01650130013009","article-title":"Papular mucinosis: a clinicopathologic study of four patients","volume":"118","author":"Farmer","year":"1982","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0190-9622(98)70567-5","article-title":"Fatal scleromyxoedema: report of a case and review of the literature","volume":"38","author":"Godby","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib23","first-page":"626","article-title":"Benenficial effect of G-CSF in scleromyxoedema associated with severe idiopathic neutropenia","volume":"135","author":"Cohen","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib24","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1126\/science.622555","article-title":"Lichen myxedematosus serum stimulates human skin fibroblast proliferation","volume":"199","author":"Harper","year":"1978","journal-title":"Science"},{"key":"10.1067\/mjd.2000.104001_bib25","first-page":"171","article-title":"Lichen myxedematosus (scleromyxoedema) serum stimutates hyaluronic acid and prostaglandin E production by human fibroblasts","volume":"12","author":"Yaron","year":"1985","journal-title":"J Rheumatol"},{"key":"10.1067\/mjd.2000.104001_bib26","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/ja01207a034","article-title":"Preparation and properties of serum and plasma proteins: a system for the separation into fractions of the protein and lipoprotein components of biological fluids","volume":"68","author":"Cohn","year":"1946","journal-title":"J Am Chem Soc"},{"issue":"Suppl","key":"10.1067\/mjd.2000.104001_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jnnp.57.Suppl.2","article-title":"Reuirements for safety and quality of intravenous immunoglobulin G preparations","volume":"57","author":"Rutter","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1067\/mjd.2000.104001_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/cei.1996.104.s1.35","article-title":"The viral safety of intravenous immune globulin","volume":"104","author":"Yap","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1067\/mjd.2000.104001_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archderm.134.1.80","article-title":"Dermatological uses of high dose intravenous immunoglobulin (hdIVIg)","volume":"134","author":"Jolles","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/cei.1996.104.s1.3","article-title":"Mechanisms of action of intravenous immune globulin in immune mediated diseases","volume":"104","author":"Mouthon","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"10.1067\/mjd.2000.104001_bib31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0190-9622(99)70544-X","article-title":"IL-4 profiles in a patient with atopic dermatitis treated with high-dose immunoglobulin","volume":"40","author":"Jolles","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1067\/mjd.2000.104001_bib32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1067\/mjd.2000.104001_bib33","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/0140-6736(93)91784-J","article-title":"Immunologically active proteins in intravenous immunoglobulin","volume":"342","author":"Lam","year":"1993","journal-title":"Lancet"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962200918450?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962200918450?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T21:23:21Z","timestamp":1759267401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962200918450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,8]]}},"alternative-id":["S0190962200918450"],"URL":"https:\/\/doi.org\/10.1067\/mjd.2000.104001","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2000,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Scleromyxedema: Response to high-dose intravenous immunoglobulin (hdIVIg)","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1067\/mjd.2000.104001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}